Thrombospondins in the tumor microenvironment

de Visser, 2023, The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth, Cancer Cell, 41, 374, 10.1016/j.ccell.2023.02.016 Brown, 1999, Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast, Clin. Cancer Res, 5, 1041 Prete, 2018, Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFbeta1 Axis, Clin. Cancer Res, 24, 6078, 10.1158/1078-0432.CCR-18-0693 Lawler, 2022, Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1, Semin Cancer Biol., 86, 126, 10.1016/j.semcancer.2022.09.006 Ghajar, 2013, The perivascular niche regulates breast tumour dormancy, Nat. Cell Biol., 15, 807, 10.1038/ncb2767 Kazerounian, 2008, Thrombospondins in cancer, Cell Mol. Life Sci., 65, 700, 10.1007/s00018-007-7486-z Adams, 2011, The thrombospondins, Cold Spring Harb. Perspect. Biol., 3, 10.1101/cshperspect.a009712 Schultz-Cherry, 1995, Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1, J. Biol. Chem., 270, 7304, 10.1074/jbc.270.13.7304 Tian, 2019, Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells, Proc. Natl. Acad. Sci. USA, 116, 19609, 10.1073/pnas.1908626116 Harada, 2021, Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer, Vivo, 35, 1693, 10.21873/invivo.12429 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med, 285, 1182, 10.1056/NEJM197111182852108 Kazerounian, 2018, Integration of pro- and anti-angiogenic signals by endothelial cells, J. Cell Commun. Signal, 12, 171, 10.1007/s12079-017-0433-3 Nguyen, 2012, Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments, BMC Cancer, 12, 522, 10.1186/1471-2407-12-522 Matuszewska, 2021, Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake, Cancers (Basel), 13, 10.3390/cancers13174444 Pereira, 2021, Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer, Front Endocrinol. (Lausanne), 12, 10.3389/fendo.2021.772349 Wiig, 2012, Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer, Physiol. Rev., 92, 1005, 10.1152/physrev.00037.2011 Heldin, 2004, High interstitial fluid pressure - an obstacle in cancer therapy, Nat. Rev. Cancer, 4, 806, 10.1038/nrc1456 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol., 23, 1011, 10.1200/JCO.2005.06.081 Masoud, 2015, HIF-1alpha pathway: role, regulation and intervention for cancer therapy, Acta Pharm. Sin. B, 5, 378, 10.1016/j.apsb.2015.05.007 Finley, 2013, Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions, J. Natl. Cancer Inst., 105, 802, 10.1093/jnci/djt093 Kut, 2007, Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, Br. J. Cancer, 97, 978, 10.1038/sj.bjc.6603923 Greenaway, 2007, Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1), J. Cell Physiol., 210, 807, 10.1002/jcp.20904 Ioachim, 2006, Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components, BMC Cancer, 6, 140, 10.1186/1471-2407-6-140 Oh, 2003, Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas, J. Dermatol., 30, 306, 10.1111/j.1346-8138.2003.tb00392.x Kosacka, 2021, Decreased thrombospondin-1 and bone morphogenetic protein-4 serum levels as potential indices of advanced stage lung cancer, J. Clin. Med, 10, 10.3390/jcm10173859 Greenaway, 2009, ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer, Mol. Cancer Ther., 8, 64, 10.1158/1535-7163.MCT-08-0864 Jimenez, 2000, Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1, Nat. Med, 6, 41, 10.1038/71517 Matuszewska, 2019, Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer, Clin. Cancer Res, 25, 1624, 10.1158/1078-0432.CCR-18-0220 Lawler, 2012, Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2, Cold Spring Harb. Perspect. Med, 2, 10.1101/cshperspect.a006627 Russell, 2015, Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer, FASEB J., 29, 576, 10.1096/fj.14-261636 Wang, 2021, Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization, Drug Discov. Today, 26, 2743, 10.1016/j.drudis.2021.07.024 Santry, 2020, Tumour vasculature: Friend or foe of oncolytic viruses?, Cytokine Growth Factor Rev., 56, 69, 10.1016/j.cytogfr.2020.07.007 Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges, Nat. Rev. Clin. Oncol., 15, 325, 10.1038/nrclinonc.2018.29 Liu, 2021, Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy, Biomed. Pharm., 139, 10.1016/j.biopha.2021.111607 Armstrong, 2002, Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism, Mol. Biol. Cell, 13, 1893, 10.1091/mbc.e01-09-0066 Koch, 2011, CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo, Breast Cancer Res Treat., 128, 337, 10.1007/s10549-010-1085-7 Rusnati, 2019, The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2), Angiogenesis, 22, 133, 10.1007/s10456-018-9644-3 Hawighorst, 2001, Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism, EMBO J., 20, 2631, 10.1093/emboj/20.11.2631 Streit, 1999, Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis, Proc. Natl. Acad. Sci. USA, 96, 14888, 10.1073/pnas.96.26.14888 Kunstfeld, 2014, Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis, J. Dermatol. Sci., 74, 106, 10.1016/j.jdermsci.2014.01.002 Streit, 2002, Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy, Cancer Res, 62, 2004 Joukov, 1996, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases, EMBO J., 15, 1751, 10.1002/j.1460-2075.1996.tb00521.x Lee, 1996, Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4, Proc. Natl. Acad. Sci. USA, 93, 1988, 10.1073/pnas.93.5.1988 Joukov, 1996, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases, EMBO J., 15, 290, 10.1002/j.1460-2075.1996.tb00359.x Hlophe, 2022, Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion, J. Cell Mol. Med, 26, 5743, 10.1111/jcmm.17571 Skobe, 2001, Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma, Am. J. Pathol., 159, 893, 10.1016/S0002-9440(10)61765-8 Skobe, 2001, Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis, Nat. Med, 7, 192, 10.1038/84643 Mandriota, 2001, Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis, EMBO J., 20, 672, 10.1093/emboj/20.4.672 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Barroso, 2020, Analyses of VEGFC/VEGF-D expressions, density and endothelial lymphatic proliferation in salivary gland neoplasms, Exp. Mol. Pathol., 113, 10.1016/j.yexmp.2020.104385 Sugiura, 2009, VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker, Int J. Oncol., 34, 673, 10.3892/ijo_00000193 Zhou, 2011, Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder, BJU Int, 107, 1930, 10.1111/j.1464-410X.2010.09725.x Cursiefen, 2011, Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes, J. Exp. Med, 208, 1083, 10.1084/jem.20092277 Van Trappen, 2002, A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer, Br. J. Cancer, 87, 537, 10.1038/sj.bjc.6600471 Detmar, 2000, Tumor angiogenesis, J. Invest. Dermatol. Symp. Proc., 5, 20, 10.1046/j.1087-0024.2000.00003.x Garnier, 2019, Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions, Front Immunol., 10, 720, 10.3389/fimmu.2019.00720 Hintzen, 2006, Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node, J. Immunol. (Baltim., Md: 1950), 177, 7346, 10.4049/jimmunol.177.10.7346 Leiriao, 2012, Monocytes as effector cells: activated Ly-6C(high) mouse monocytes migrate to the lymph nodes through the lymph and cross-present antigens to CD8+ T cells, Eur. J. Immunol., 42, 2042, 10.1002/eji.201142166 Brown, 2010, Chemoattractant receptors and lymphocyte egress from extralymphoid tissue: changing requirements during the course of inflammation, J. Immunol. (Baltim., Md: 1950), 185, 4873, 10.4049/jimmunol.1000676 Gascoigne, 2016, TCR Signal Strength and T Cell Development, Annu Rev. Cell Dev. Biol., 32, 327, 10.1146/annurev-cellbio-111315-125324 Stylianopoulos, 2013, Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse, Cancer Res, 73, 3833, 10.1158/0008-5472.CAN-12-4521 Leu, 2000, Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation, Cancer Res, 60, 4324 Wu, 2013, The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems, J. Theor. Biol., 320, 131, 10.1016/j.jtbi.2012.11.031 Lunt, 2008, Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours, BMC Cancer, 8, 2, 10.1186/1471-2407-8-2 Stapleton, 2015, The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation, J. Control Release, 211, 163, 10.1016/j.jconrel.2015.06.008 Jain, 2001, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy, Nat. Med, 7, 987, 10.1038/nm0901-987 Armulik, 2005, Endothelial/pericyte interactions, Circ. Res, 97, 512, 10.1161/01.RES.0000182903.16652.d7 Andrae, 2008, Role of platelet-derived growth factors in physiology and medicine, Genes Dev., 22, 1276, 10.1101/gad.1653708 Gaengel, 2009, Endothelial-mural cell signaling in vascular development and angiogenesis, Arterioscler. Thromb. Vasc. Biol., 29, 630, 10.1161/ATVBAHA.107.161521 Helkin, 2015, Thrombospondin-1, -2 and -5 have differential effects on vascular smooth muscle cell physiology, Biochem Biophys. Res Commun., 464, 1022, 10.1016/j.bbrc.2015.07.044 Kassem, 2019, Thrombospondins Differentially Regulate Proteins Involved in Arterial Remodeling, Physiol. Res, 68, 893, 10.33549/physiolres.934148 Bodewes, 2017, Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model, FASEB J., 31, 109, 10.1096/fj.201600501r Majack, 1988, Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation, J. Cell Biol., 106, 415, 10.1083/jcb.106.2.415 Scheef, 2009, Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1, Am. J. Physiol. Cell Physiol., 296, C724, 10.1152/ajpcell.00409.2008 Isenberg, 2005, Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor, Matrix Biol., 24, 110, 10.1016/j.matbio.2005.01.002 Wu, 2006, Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens, Dev. Dyn., 235, 1908, 10.1002/dvdy.20837 Sorenson, 2021, Targeted Thrombospondin-1 Expression in Ocular Vascular Development and Neovascularization, Front Cell Dev. Biol., 9, 10.3389/fcell.2021.671989 Iesato, 2023, The tyrosine kinase inhibitor lenvatinib inhibits anaplastic thyroid carcinoma growth by targeting pericytes in the tumor microenvironment, Thyroid, 10.1089/thy.2022.0597 Czekay, 2022, Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets, Cancers (Basel), 14, 10.3390/cancers14051231 Matsumura, 2022, Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-beta signal activation in pancreatic ductal adenocarcinoma, Transl. Oncol., 26, 10.1016/j.tranon.2022.101533 Murphy-Ullrich, 2019, Thrombospondin 1 and its diverse roles as a regulator of extracellular matrix in fibrotic disease, J. Histochem Cytochem, 67, 683, 10.1369/0022155419851103 Yoshihara, 2020, Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway, Int J. Cancer, 146, 2268, 10.1002/ijc.32854 Kitami, 2022, Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-beta1/thrombospondin-1 axis, Matrix Biol., 109, 70, 10.1016/j.matbio.2022.03.003 Kaur, 2021, Functions of Thrombospondin-1 in the Tumor Microenvironment, Int J. Mol. Sci., 22, 10.3390/ijms22094570 Yee, 2009, The effect of thrombospondin-1 on breast cancer metastasis, Breast Cancer Res Treat., 114, 85, 10.1007/s10549-008-9992-6 Leca, 2016, Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness, J. Clin. Invest, 126, 4140, 10.1172/JCI87734 Kuriyama, 2020, Extracellular Vesicles Are Key Regulators of Tumor Neovasculature, Front Cell Dev. Biol., 8, 10.3389/fcell.2020.611039 Balint, 2020, Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells, Science, 368, 897, 10.1126/science.aay9207 Le Large, 2020, Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach, Oncologist, 25, e634, 10.1634/theoncologist.2019-0680 Nan, 2022, Tumor-stroma TGF-beta1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin alpha(v)beta(3)/CD36-mediated activation of the MAPK pathway, Cancer Lett., 528, 59, 10.1016/j.canlet.2021.12.025 Xu, 2022, Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma, Int J. Biol. Sci., 18, 5038, 10.7150/ijbs.70083 McCart Reed, 2013, Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer, Virchows Arch., 463, 535, 10.1007/s00428-013-1468-3 Tveitaras, 2019, Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model, PLoS One, 14, 10.1371/journal.pone.0215909 Muppala, 2017, Thrombospondin-4 mediates TGF-beta-induced angiogenesis, Oncogene, 36, 5189, 10.1038/onc.2017.140 Muppala, 2021, Thrombospondin-4 mediates hyperglycemia- and TGF-beta-induced inflammation in breast cancer, Int J. Cancer, 148, 2010, 10.1002/ijc.33439 Shi, 2021, Thrombospondin 4/integrin alpha2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells, J. Exp. Clin. Cancer Res, 40, 14, 10.1186/s13046-020-01812-7 Cui, 2022, Cartilage Oligomeric Matrix Protein, Diseases, and Therapeutic Opportunities, Int J. Mol. Sci., 23, 10.3390/ijms23169253 Li, 2018, HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways, J. Exp. Clin. Cancer Res, 37, 231, 10.1186/s13046-018-0908-y Englund, 2016, Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer, Oncogene, 35, 5585, 10.1038/onc.2016.98 Englund, 2017, Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis, Oncotarget, 8, 98298, 10.18632/oncotarget.21176 Ma, 2022, The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer, Biomolecules, 13, 10.3390/biom13010062 Guo, 2023, Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types, Clin. Transl. Oncol., 25, 535, 10.1007/s12094-022-02968-8 Chen, 2005, Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins, J. Biol. Chem., 280, 32655, 10.1074/jbc.M504778200 Morandi, 2021, Endothelial Cell Behavior Is Determined by Receptor Clustering Induced by Thrombospondin-1, Front Cell Dev. Biol., 9, 10.3389/fcell.2021.664696 Papadakos, 2021, High Levels of Expression of Cartilage Oligomeric Matrix Protein in Lymph Node Metastases in Breast Cancer Are Associated with Reduced Survival, Cancers (Basel), 13, 10.3390/cancers13235876 Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res, 66, 605, 10.1158/0008-5472.CAN-05-4005 Zhou, 2020, Tumor-Associated Macrophages: Recent Insights and Therapies, Front Oncol., 10, 188, 10.3389/fonc.2020.00188 Isenberg, 2009, Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies, Nat. Rev. Cancer, 9, 182, 10.1038/nrc2561 Martin-Manso, 2008, Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells, Cancer Res, 68, 7090, 10.1158/0008-5472.CAN-08-0643 Zhao, 2014, Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury, Mucosal Immunol., 7, 440, 10.1038/mi.2013.63 Stein, 2016, Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1beta Production and Activation through CD47, Sci. Rep., 6, 19684, 10.1038/srep19684 Mirlekar, 2021, IL-12 Family Cytokines in Cancer and Immunotherapy, Cancers (Basel), 13, 10.3390/cancers13020167 Cho, 2011, Gene expression signature-based prognostic risk score in gastric cancer, Clin. Cancer Res, 17, 1850, 10.1158/1078-0432.CCR-10-2180 Pluskota, 2005, Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function, Blood, 106, 3970, 10.1182/blood-2005-03-1292 Frolova, 2010, Thrombospondin-4 regulates vascular inflammation and atherogenesis, Circ. Res, 107, 1313, 10.1161/CIRCRESAHA.110.232371 Ortiz-Masia, 2012, Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process, PLoS One, 7, 10.1371/journal.pone.0048535 Biswas, 2008, Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms, J. Immunol., 180, 2011, 10.4049/jimmunol.180.4.2011 Harmey, 1998, Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1, Ann. Surg. Oncol., 5, 271, 10.1007/BF02303785 Margosio, 2003, Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2, Blood, 102, 4399, 10.1182/blood-2003-03-0893 Gajeton, 2021, Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer, Cancers (Basel), 13, 10.3390/cancers13061346 Chung, 2021, Correlation between Oxidative Stress and Transforming Growth Factor-Beta in Cancers, Int J. Mol. Sci., 22, 10.3390/ijms222413181 Daniel, 2013, Long-term gene therapy with thrombospondin 2 inhibits TGF-beta activation, inflammation and angiogenesis in chronic allograft nephropathy, PLoS One, 8, 10.1371/journal.pone.0083846 Murphy-Ullrich, 2018, Thrombospondin-1 regulation of latent TGF-beta activation: A therapeutic target for fibrotic disease, Matrix Biol., 68–69, 28, 10.1016/j.matbio.2017.12.009 Stenina-Adognravi, 2018, Thrombospondins and remodeling of the tumor microenvironment, Vessel, 2 Yamauchi, 2002, Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937, Biochem Biophys. Res Commun., 290, 1551, 10.1006/bbrc.2002.6386 Rege, 2009, Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1, J. Cell Physiol., 218, 94, 10.1002/jcp.21570 Lopez-Dee, 2011, Thrombospondin-1: multiple paths to inflammation, Mediat. Inflamm., 2011, 10.1155/2011/296069 Li, 2002, Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior, J. Cell Biol., 157, 509, 10.1083/jcb.200109098 Kaur, 2014, CD47 signaling regulates the immunosuppressive activity of VEGF in T cells, J. Immunol., 193, 3914, 10.4049/jimmunol.1303116 Miller, 2013, Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation, Matrix Biol., 32, 316, 10.1016/j.matbio.2013.02.009 Jeanne, 2021, Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity, Cancers (Basel), 13, 10.3390/cancers13195019 Calvillo-Rodriguez, 2022, PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells, Oncoimmunology, 11, 10.1080/2162402X.2022.2054305 Soto-Pantoja, 2014, CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy, Cancer Res, 74, 6771, 10.1158/0008-5472.CAN-14-0037-T Lawler, 1986, The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins, J. Cell Biol., 103, 1635, 10.1083/jcb.103.5.1635 Lawler, 1988, Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors, J. Cell Biol., 107, 2351, 10.1083/jcb.107.6.2351 Lahav, 1988, Thrombospondin inhibits adhesion of endothelial cells, Exp. Cell Res, 177, 199, 10.1016/0014-4827(88)90037-7 Murphy-Ullrich, 1989, Thrombospondin modulates focal adhesions in endothelial cells, J. Cell Biol., 109, 1309, 10.1083/jcb.109.3.1309 Taraboletti, 1990, Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor, J. Cell Biol., 111, 765, 10.1083/jcb.111.2.765 Bagavandoss, 1990, Specific inhibition of endothelial cell proliferation by thrombospondin, Biochem Biophys. Res Commun., 170, 867, 10.1016/0006-291X(90)92171-U Good, 1990, A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin, Proc. Natl. Acad. Sci. USA, 87, 6624, 10.1073/pnas.87.17.6624 Lawler, 2001, Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice, Am. J. Pathol., 159, 1949, 10.1016/S0002-9440(10)63042-8 Matuszewska, 2022, Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer, Gynecol. Oncol., 164, 154, 10.1016/j.ygyno.2021.11.006 Pinessi, 2016, PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1, Thromb. Res, 140, S182, 10.1016/S0049-3848(16)30148-7